| Labcorp

November 13, 2022

Validation of an Appropriate Healthy Diet for Xenopus laevis Used in Endocrine Studies

SETAC North America 2022 -- Two significant OECD guidelines for endocrine disruption in non-target organisms are the OECD 231 and OECD 241, both using the test species of Xenopus laevis. Despite these being a model species, they are not a species routinely used in Contract Research Organisations (CROs), as routine testing is unusual in frog species.

November 13, 2022

Fish Metabolism Studies and Their Potential Use in Environmental Safety Testing

SETAC North America 2022 -- With the increasing popularity of fish-based diets, a large proportion of fish we eat comes from fish farms. The diet used in these farms often comprises a substantial portion of plant commodities, leading to a potential risk of exposure to pesticide residues.

November 13, 2022

Effective Waiver Strategies for Environmental Risk Assessment of Pharmaceuticals in the European Union

ACT 2022 -- An environmental risk assessment (ERA) is mandatory for marketing authorisation of pharmaceuticals in the European Union (EU), following the European Medicines Agency (EMA) guidelines. In most cases, a costly program of physico-chemical, environmental fate and effects testing is required.

November 13, 2022

Survey of Rodent Motor Disturbances on Preclinical Studies

ACT 2022 -- Rodent motor disturbances observed on preclinical toxicology and carcinogenicity studies may lead to challenging assessments when determining if observations are drug-related or background.

November 14, 2022

Exploring the realities of health equity and diversity in cancer clinical trials

Only around 5%-13% of people who take part in cancer trials are Black or African American, Asian, or Hispanic, compared with 75% of white people. Labcorp is committed to addressing healthcare disparities, improving diversity in clinical trials and making clinical trials accessible for all.

November 16, 2022

Assessing the Feasibility and Impact of Singlicate-Based Analysis for Clinical ADA Sample Analysis

EBF Open Symposium 2022 -- The traditional approach to generating sample results in ligand-binding assays has been to make 'duplicate' measurements from two adjacent wells on the same immunoassay plate.

November 16, 2022

Reaching the Next Level of Sensitivity in Oligonucleotide Bioanalysis: A Hybridization-Based Method on Simoa®

EBF Open Symposium 2022 -- Simoa®, Single Molecule Array technology, is known and recognized as an ultra-sensitive immunoassay technology that can detect extremely low level of proteins and nucleic acids that traditional ligand binding assay cannot reach.

November 16, 2022

Detection of Antibodies to AAVs Using Gyrolab® System

EBF Open Symposium 2022 -- Adeno-associated viruses (AAVs) are one of most popular and promising tools for gene therapy with several products already approved for treatment of human genetic diseases. Due to natural infection, pre-existing anti-AAV antibodies widely exist in humans and many animal models. This poses hurdles to the AAV-based gene therapy.

November 22, 2022

Cross-Platform Validation for Paroxysmal Nocturnal Hemoglobinuria Diagnosis

AFC 2022 -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disease characterized by populations of blood cells, called PNH clones, unable to express glycosylphosphatidyl-inositol (GPI)-linked proteins.

November 28, 2022

New Approach Methods

In recognition of scientific pursuits to reduce vertebrate animal testing, Labcorp is helping lead innovation in New Approach Methods (NAMs), also known as nonanimal approaches.This includes an array of in vitro test methods and in silico alternatives used to evaluate your substances during early development or to answer regulatory questions.

Managing Your Health

Diseases & Specialties

Treatment Methods & Product Testing

Lab Disciplines & Services

Validation of an Appropriate Healthy Diet for Xenopus laevis Used in Endocrine Studies

Fish Metabolism Studies and Their Potential Use in Environmental Safety Testing

Effective Waiver Strategies for Environmental Risk Assessment of Pharmaceuticals in the European Union

Survey of Rodent Motor Disturbances on Preclinical Studies

Exploring the realities of health equity and diversity in cancer clinical trials

Assessing the Feasibility and Impact of Singlicate-Based Analysis for Clinical ADA Sample Analysis

Reaching the Next Level of Sensitivity in Oligonucleotide Bioanalysis: A Hybridization-Based Method on Simoa®

Detection of Antibodies to AAVs Using Gyrolab® System

Cross-Platform Validation for Paroxysmal Nocturnal Hemoglobinuria Diagnosis

New Approach Methods